RETN and breast carcinoma: Although, resistin’s diagnostic performance was not significant based on ROC curve analysis [0.680, 95% CI: 0.470–0.890, p = 0.110], the diagnostic performance of IL-6 was significant based on ROC curve analysis [0.825, 95% CI: 0.549–0.947, p = 0.030); thus, IL-6 might be considered as a breast cancer biomarker that reflecting an early and inflammatory stage of the disease (Table 4).